Therapeutic apheresis : official journal of the International Society for Apheresis and the Japanese Society for Apheresis最新文献_第5页

Membranes for therapeutic apheresis. 用于治疗性分离的膜。

Therapeutic apheresis : official journal of the International Society for Apheresis and the Japanese Society for Apheresis Pub Date : 2002-08-01 DOI: 10.1046/J.1526-0968.2002.00442.X

S. Nakaji, Tsuneatsu Yamamoto

引用次数: 25

Leukocyte Apheresis Using a Centrifugal Cell Separator in Refractory Ulcerative Colitis: A Multicenter Open Label Trial 使用离心细胞分离器进行白细胞分离治疗难治性溃疡性结肠炎:一项多中心开放标签试验

Therapeutic apheresis : official journal of the International Society for Apheresis and the Japanese Society for Apheresis Pub Date : 2002-08-01 DOI: 10.1046/J.1526-0968.2002.00441.X

Y. Kohgo, H. Hibi, T. Chiba, T. Shimoyama, T. Muto, K. Yamamura, M. Popovsky

{"title":"Leukocyte Apheresis Using a Centrifugal Cell Separator in Refractory Ulcerative Colitis: A Multicenter Open Label Trial","authors":"Y. Kohgo, H. Hibi, T. Chiba, T. Shimoyama, T. Muto, K. Yamamura, M. Popovsky","doi":"10.1046/J.1526-0968.2002.00441.X","DOIUrl":"https://doi.org/10.1046/J.1526-0968.2002.00441.X","url":null,"abstract":"Recently, successful results of ulcerative colitis (UC) treatments with leukocyte apheresis have been reported by several institutes. To certify the efficacy of leukocyte apheresis in refractory UC patients, a multicenter open label trial was conducted, and results were analyzed. Fifty patients diagnosed with active steroid-resistant UC were enrolled in this study from 14 medical centers. Using a centrifugal cell separator (Component Collection System, Haemonetics), leukocyte apheresis was performed once a week for 5 weeks. General conditions and abdominal symptoms were recorded daily, and laboratory tests were followed weekly. Changes of colonoscopic and histological manifestations of luminal activity through the study period were evaluated. At the end of the study period, stool frequency was decreased to less than 4 times a day in 68.4% (26 of 38) and serum C-reactive protein (CRP) concentration was normalized in 56.7% (17 of 30) of the patients. Colonoscopic remission was achieved in 57.7% (26 of 45), and histological improvement was noted in 54.1% (20 of 37) of the patients tested. Improved disease activity was demonstrated in 74% (37 of 50) of the patients by general assessment criteria. Analysis of the trial data confirmed the valid clinical efficacy of leukocyte apheresis by centrifugal cell separator in refractory UC patients.","PeriodicalId":79755,"journal":{"name":"Therapeutic apheresis : official journal of the International Society for Apheresis and the Japanese Society for Apheresis","volume":"6 1","pages":"255-260"},"PeriodicalIF":0.0,"publicationDate":"2002-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1046/J.1526-0968.2002.00441.X","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"57734487","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 20

Combination of therapeutic apheresis and therapeutic ventricular assistance for end-stage heart failure patients. 治疗性离心分离与治疗性心室辅助联合治疗终末期心力衰竭患者。

Therapeutic apheresis : official journal of the International Society for Apheresis and the Japanese Society for Apheresis Pub Date : 2002-08-01 DOI: 10.1046/J.1526-0968.2002.00444.X

S. Schulte-Eistrup, S. Ashizawa, K. Nonaka, S. Ichikawa, T. Motomura, N. Murai, Y. Nosé

{"title":"Combination of therapeutic apheresis and therapeutic ventricular assistance for end-stage heart failure patients.","authors":"S. Schulte-Eistrup, S. Ashizawa, K. Nonaka, S. Ichikawa, T. Motomura, N. Murai, Y. Nosé","doi":"10.1046/J.1526-0968.2002.00444.X","DOIUrl":"https://doi.org/10.1046/J.1526-0968.2002.00444.X","url":null,"abstract":"Dilated cardiomyopathy is a cardiac disease of unknown origin which is characterized by the gradual development of cardiac failure associated with four-chamber dilatation of the heart. Heart transplantation has been considered as the last resort for this disease. However, some patients who received support with a ventricular assist device (VAD) as a bridge-to-transplantation and then recovered without transplantation have been reported. This new concept of treating heart failure is termed bridge-to-recovery. A VAD can inhibit the heart failure compensatory mechanisms by extreme ventricular unloading. Also, heart failure is a complex neurohormonal/autocrine-paracrine syndrome, and these mechanisms consecutively lead to inflammatory response by proinflammatory cytokines; interleukin-1 alpha (IL-1 alpha), interleukin-1 beta (IL-1 beta), interleukin-2 (IL-2), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-alpha). Furthermore, the existence of anti-beta1-adrenoceptor autoantibodies (A-beta1-AABs) in a patient with dilated cardiomyopathy has been reported. These proinflammatory cytokines and this antibody accelerate a ventricular remodeling and a contractile dysfunction over the long term. Apheresis can also inhibit the vicious cycle in heart failure by removing the factors that are produced by activated neurohormonal/autocrine-paracrine compensatory mechanisms. Therefore, we propose that the combined therapies, therapeutic VAD and therapeutic apheresis, will provide a prominent outcome for a patient who is suffering from end-stage heart failure.","PeriodicalId":79755,"journal":{"name":"Therapeutic apheresis : official journal of the International Society for Apheresis and the Japanese Society for Apheresis","volume":"21 1","pages":"247-54"},"PeriodicalIF":0.0,"publicationDate":"2002-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"83333345","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Plasma adsorption in critical care. 重症监护中的血浆吸附。

Therapeutic apheresis : official journal of the International Society for Apheresis and the Japanese Society for Apheresis Pub Date : 2002-06-01 DOI: 10.1046/J.1526-0968.2002.00429.X

Kwangseok Yang, Kazuo Kenpe, K. Yamaji, H. Tsuda, H. Hashimoto

引用次数: 27

Plasma exchange in patients with toxic epidermal necrolysis. 中毒性表皮坏死松解患者血浆置换。

Therapeutic apheresis : official journal of the International Society for Apheresis and the Japanese Society for Apheresis Pub Date : 2002-06-01 DOI: 10.1046/J.1526-0968.2002.00409.X

G. Bamichas, T. Natse, Fotini Christidou, Maria Stangou, A. Karagianni, S. Koukourikos, G. Chaidemenos, F. Chrysomallis, Kostas Sombolos

引用次数: 75

Critical care by cytapheresis. 用细胞分离术进行重症监护。

Therapeutic apheresis : official journal of the International Society for Apheresis and the Japanese Society for Apheresis Pub Date : 2002-06-01 DOI: 10.1046/J.1526-0968.2002.00433.X

A. Kawamura, S. Tsuchihashi, M. Yonekawa, M. Saitoh, T. Tamaki, J. Meguro, K. Kukita

引用次数: 0

Critical care apheresis. 重症监护血浆。

Therapeutic apheresis : official journal of the International Society for Apheresis and the Japanese Society for Apheresis Pub Date : 2002-06-01 DOI: 10.1046/J.1526-0968.2002.00230.X

H. Hirasawa

引用次数: 1

Influence of single low-density lipoprotein apheresis on the adhesion molecules soluble vascular cellular adhesion molecule-1, soluble intercellular adhesion molecule-1, and P-selectin. 单次低密度脂蛋白分离对粘附分子可溶性血管细胞粘附分子-1、可溶性细胞间粘附分子-1和p -选择素的影响。

Therapeutic apheresis : official journal of the International Society for Apheresis and the Japanese Society for Apheresis Pub Date : 2002-06-01 DOI: 10.1046/J.1526-0968.2002.00405.X

E. Pulawski, K. Mellwig, T. Brinkmann, K. Kleesiek, D. Horstkotte

{"title":"Influence of single low-density lipoprotein apheresis on the adhesion molecules soluble vascular cellular adhesion molecule-1, soluble intercellular adhesion molecule-1, and P-selectin.","authors":"E. Pulawski, K. Mellwig, T. Brinkmann, K. Kleesiek, D. Horstkotte","doi":"10.1046/J.1526-0968.2002.00405.X","DOIUrl":"https://doi.org/10.1046/J.1526-0968.2002.00405.X","url":null,"abstract":"The aim of our study was to investigate the influence of single low-density lipoprotein apheresis (heparin extracorporeal low-density lipoprotein precipitation [HELP]procedure) on plasma concentrations of soluble adhesion molecules (sAMs) such as soluble vascular cellular adhesion molecule-1 (sVCAM-1), soluble intercellular adhesion molecule-1 (sICAM-1), and P-selectin in patients with familial heterozygous hypercholesterolemia and documented coronary artery disease enrolled in a chronic weekly HELP apheresis. Before HELP apheresis, the mean plasma concentration of sVCAM-1 was 515 +/- 119 ng/ml, 204 +/- 58 ng/ml for sICAM-1, and 112 +/- 45 ng/ml for P-selectin. After single HELP apheresis, plasma concentrations of sAM declined significantly by 32 +/- 7%, 18 +/- 15%, and 33 +/- 25% for sVCAM- 1,sICAM-1 and P-selectin, respectively. After a 1 week interval, sAM concentrations rose to approximately the initial values. The concentrations of all sAMs studied were significantly lower in the plasma leaving than entering the filter. Due to filtration, the decline in plasma level of sVCAM-1, sICAM-1, and P-selectin was 62 +/- 19%, 51 +/- 39%, and 67 +/- 22%, respectively. In addition to lipid reduction, single HELP apheresis significantly lowers plasma concentrations of sVCAM-1, sICAM-1, and P-selectin.","PeriodicalId":79755,"journal":{"name":"Therapeutic apheresis : official journal of the International Society for Apheresis and the Japanese Society for Apheresis","volume":"18 1","pages":"229-33"},"PeriodicalIF":0.0,"publicationDate":"2002-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82437222","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 18

Long-term survivors with artificial liver support in fulminant hepatic failure. 暴发性肝衰竭中人工肝支持的长期存活者。

Therapeutic apheresis : official journal of the International Society for Apheresis and the Japanese Society for Apheresis Pub Date : 2002-06-01 DOI: 10.1046/J.1526-0968.2002.00434.X

Masakazu Nitta, H. Hirasawa, S. Oda, H. Shiga, K. Nakanishi, K. Matsuda, Masataka Nakamura, K. Yokohari, Takeshi Hirano, Y. Hirayama, T. Moriguchi, E. Watanabe

{"title":"Long-term survivors with artificial liver support in fulminant hepatic failure.","authors":"Masakazu Nitta, H. Hirasawa, S. Oda, H. Shiga, K. Nakanishi, K. Matsuda, Masataka Nakamura, K. Yokohari, Takeshi Hirano, Y. Hirayama, T. Moriguchi, E. Watanabe","doi":"10.1046/J.1526-0968.2002.00434.X","DOIUrl":"https://doi.org/10.1046/J.1526-0968.2002.00434.X","url":null,"abstract":"Clinical ability of artificial liver support (ALS) has been improved greatly in recent years which has allowed us to encounter long-term survivors with fulminant hepatic failure (FHF) whose liver function has been almost completely lost. This suggests that application of ALS in patients with FHF gains time while awaiting transplantation as well as time for functional recovery and regeneration of the liver graft following receipt of the graft with marginal function and/or size. Thus, ALS will contribute greatly to extending the indications for liver transplantation and increase the number of patients receiving and benefiting from this treatment. On the other hand, introduction of ALS prolongs the duration of intensive treatment which increases the risk of infection and increases medical costs. In addition, when to discontinue intensive treatment of patients whose level of consciousness is maintained only by ALS is controversial. Thus, further investigation will be needed to establish a consensus on indications for long-term ALS in FHF.","PeriodicalId":79755,"journal":{"name":"Therapeutic apheresis : official journal of the International Society for Apheresis and the Japanese Society for Apheresis","volume":"66 1","pages":"208-12"},"PeriodicalIF":0.0,"publicationDate":"2002-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74549766","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 15

Double filtration plasmapheresis in critical care. 双重过滤血浆置换在重症监护中的应用。

Therapeutic apheresis : official journal of the International Society for Apheresis and the Japanese Society for Apheresis Pub Date : 2002-06-01 DOI: 10.1046/J.1526-0968.2002.00428.X

M. Mineshima, T. Akiba

{"title":"Double filtration plasmapheresis in critical care.","authors":"M. Mineshima, T. Akiba","doi":"10.1046/J.1526-0968.2002.00428.X","DOIUrl":"https://doi.org/10.1046/J.1526-0968.2002.00428.X","url":null,"abstract":"Many kinds of technologies have been introduced and successfully developed for therapeutic apheresis. Furthermore, several kinds of these technologies have also been applied in critical care. Double filtration plasmapheresis (DFPP), however, is rarely applied in this field in comparison with other treatments such as continuous hemofiltration, continuous hemodiafiltration, single filtration plasmapheresis, and plasma adsorption therapies. In this paper, the characteristics of the DFPP treatments for critical care are summarized. During the DFPP treatments, the patient's blood volume (BV) often decreases with time due to albumin loss induced by inadequate albumin infusion in a supplementation fluid. We examined the change of BV by a continuous hematocrit monitor, Crit-Line, during an in vivo study for 9 patients. As a result, albumin loss fairly occurred in DFPP treatments. The decrease of patient BV was induced by an oncotic pressure drop due to albumin loss and often resulted in a blood pressure drop. This is a serious problem for DFPP in critical care. We should avoid inadequate albumin infusion if the patient is suffering from these adverse effects. In order to determine the optimal concentration C(S) and volume V(S) values of a supplemented albumin solution, we introduced a variable blood volume model for albumin transport in DFPP.","PeriodicalId":79755,"journal":{"name":"Therapeutic apheresis : official journal of the International Society for Apheresis and the Japanese Society for Apheresis","volume":"72 1","pages":"180-3"},"PeriodicalIF":0.0,"publicationDate":"2002-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86142869","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 10